{"id":"levofolinic-acid","rwe":[{"pmid":"40089969","year":"2025","title":"A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study.","finding":"","journal":"Drugs & aging","studyType":"Clinical Study"},{"pmid":"36793106","year":"2023","title":"Strategic use of levofolinic acid for methotrexate-induced side effects in juvenile idiopathic arthritis: a prospective observational study.","finding":"","journal":"Pediatric rheumatology online journal","studyType":"Clinical Study"},{"pmid":"32381870","year":"2020","title":"[A Case of a Migrating Central Venous Catheter in the Internal Jugular Vein Diagnosed Using Ultrasonography in a Patient with Right-Sided NeckPain during Chemotherapy].","finding":"","journal":"Gan to kagaku ryoho. Cancer & chemotherapy","studyType":"Clinical Study"},{"pmid":"31394027","year":"2019","title":"Toxoplasma gondii-induced brachial plexus neuropathy after allogeneic hematopoietic stem cell transplantation.","finding":"","journal":"Transplant infectious disease : an official journal of the Transplantation Society","studyType":"Clinical Study"},{"pmid":"28685492","year":"2018","title":"Role of Intramuscular Levofolinate Administration in the Treatment of Hereditary Folate Malabsorption: Report of Three Cases.","finding":"","journal":"JIMD reports","studyType":"Clinical Study"}],"tags":[{"label":"Folate Analog","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"V03AF04","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","category":"indication"},{"label":"Bone Marrow Suppression due to Folic Acid Antagonism","category":"indication"},{"label":"Folic acid deficiency","category":"indication"},{"label":"Malignant tumor of stomach","category":"indication"},{"label":"Megaloblastic anemia","category":"indication"},{"label":"Methotrexate Toxicity","category":"indication"},{"label":"Spectrum Pharms","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Antidotes","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":721.429,"date":"","count":196,"signal":"Dermatitis acneiform","source":"DrugCentral FAERS","actionTaken":"Reported 196 times (LLR=721)"},{"llr":570.991,"date":"","count":156,"signal":"Paronychia","source":"DrugCentral FAERS","actionTaken":"Reported 156 times (LLR=571)"},{"llr":531.141,"date":"","count":282,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 282 times (LLR=531)"},{"llr":365.233,"date":"","count":237,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 237 times (LLR=365)"},{"llr":359.688,"date":"","count":125,"signal":"Peripheral sensory neuropathy","source":"DrugCentral FAERS","actionTaken":"Reported 125 times (LLR=360)"},{"llr":327.352,"date":"","count":338,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 338 times (LLR=327)"},{"llr":315.096,"date":"","count":359,"signal":"Decreased appetite","source":"DrugCentral FAERS","actionTaken":"Reported 359 times (LLR=315)"},{"llr":286.345,"date":"","count":244,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 244 times (LLR=286)"},{"llr":269.717,"date":"","count":230,"signal":"Stomatitis","source":"DrugCentral FAERS","actionTaken":"Reported 230 times (LLR=270)"},{"llr":199.578,"date":"","count":75,"signal":"Hyperammonaemia","source":"DrugCentral FAERS","actionTaken":"Reported 75 times (LLR=200)"},{"llr":194.925,"date":"","count":113,"signal":"Hypomagnesaemia","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=195)"},{"llr":187.174,"date":"","count":486,"signal":"Diarrhoea","source":"DrugCentral FAERS","actionTaken":"Reported 486 times (LLR=187)"},{"llr":148.533,"date":"","count":33,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=149)"},{"llr":141.755,"date":"","count":192,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 192 times (LLR=142)"},{"llr":136.938,"date":"","count":86,"signal":"Skin disorder","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=137)"}],"commonSideEffects":[],"specialPopulations":{"Lactation":"There are no data on the presence of levoleucovorin in human milk or its effects on the breastfed infant or on milk production. Levoleucovorin is administered in combination with methotrexate or fluorouracil. Refer to methotrexate and fluorouracil prescribing information for additional information.","Pregnancy":"There are limited data with levoleucovorin use in pregnant women. Animal reproduction studies have not been conducted with levoleucovorin. Levoleucovorin is administered in combination with methotrexate or fluorouracil, which can cause embryo-fetal harm. Refer to methotrexate and fluorouracil prescribing information for additional information. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Geriatric use":"Clinical studies of levoleucovorin injection in the treatment of osteosarcoma did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. In the NCCTG clinical trial of levoleucovorin injection in combination with 5-FU in advanced colorectal cancer, adverse reactions were consistent with 5-FU related toxicity and were similar for patients age 65 and older and for patients younger than age 65.","Paediatric use":"The safety and effectiveness of levoleucovorin have been established in pediatric patients for rescue after high-dose methotrexate therapy in osteosarcoma and diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination. Use of levoleucovorin in pediatric patients is supported by open-label clinical trial data in 16 pediatric patients years of age and older, with additional supporting evidence from literature [see Clinical Studies 14.1)]. The safety and effectiveness of levoleucovorin have not been established for pediatric patients younger than 2 years of age."}},"trials":[],"aliases":[],"company":"Spectrum Pharms","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2039-03-25","territory":"US","patentNumber":"11541012"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Levofolinic acid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:45:59.956454+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:45:59.955990+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Levofolinic Acid","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:46:14.127503+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:46:11.833668+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levofolinic acid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:46:12.704999+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1908841/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:46:14.011086+00:00"}},"allNames":"fusilev","offLabel":[],"synonyms":["levoleucovorin calcium pentahydrate","levoleucovorin","calcium levofolinate","levoleucovorin calcium","levofolene","L-Folinic acid","levofolinic acid","sodium levofolinate","calcium levofolinate hydrate"],"timeline":[{"date":"2008-03-07","type":"positive","source":"DrugCentral","milestone":"FDA approval (Spectrum Pharms)"},{"date":"2018-09-21","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Pfizer Japan Inc.)"}],"aiSummary":"Fusilev (Levofolinic acid) is a folate analog small molecule developed by Spectrum Pharmaceuticals. It is used as an adjunct to fluorouracil treatment of colorectal cancer and to treat various conditions including bone marrow suppression, folic acid deficiency, and methotrexate toxicity. Fusilev is FDA-approved and has been on the market since 2008. The commercial status of Fusilev is patented, and it is used to counteract the toxic effects of certain chemotherapy agents. Key safety considerations include its potential to exacerbate certain conditions.","approvals":[{"date":"2008-03-07","orphan":true,"company":"SPECTRUM PHARMS","regulator":"FDA"},{"date":"2018-09-21","orphan":false,"company":"Pfizer Japan Inc.","regulator":"PMDA"}],"brandName":"Fusilev","ecosystem":[{"indication":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","otherDrugs":[{"name":"leucovorin","slug":"leucovorin","company":""}],"globalPrevalence":1900000},{"indication":"Bone Marrow Suppression due to Folic Acid Antagonism","otherDrugs":[{"name":"leucovorin","slug":"leucovorin","company":""}],"globalPrevalence":null},{"indication":"Folic acid deficiency","otherDrugs":[{"name":"folic acid","slug":"folic-acid","company":"Lederle"},{"name":"leucovorin","slug":"leucovorin","company":""}],"globalPrevalence":null},{"indication":"Malignant tumor of stomach","otherDrugs":[{"name":"capecitabine","slug":"capecitabine","company":"Hoffmann La Roche"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"nivolumab","slug":"nivolumab","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Megaloblastic anemia","otherDrugs":[{"name":"leucovorin","slug":"leucovorin","company":""}],"globalPrevalence":null},{"indication":"Methotrexate Toxicity","otherDrugs":[{"name":"leucovorin","slug":"leucovorin","company":""}],"globalPrevalence":240000},{"indication":"Pyrimethamine Toxicity","otherDrugs":[{"name":"leucovorin","slug":"leucovorin","company":""}],"globalPrevalence":null},{"indication":"Small intestine cancer","otherDrugs":[{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"oxaliplatin","slug":"oxaliplatin","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Folate Analog","explanation":"","oneSentence":"","technicalDetail":"Fusilev (levofolinic acid) is a racemic mixture of the L-isomer of folic acid, which is a necessary co-factor for the enzyme dihydrofolate reductase (DHFR). By providing a source of L-folinic acid, Fusilev helps to bypass the inhibitory effects of certain chemotherapy agents on DHFR, allowing for the continued synthesis of DNA and RNA."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Folinic_acid","title":"Folinic acid","extract":"Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, and may be used to treat folate deficiency, anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.","wiki_history":"== History ==\nFolinic acid was discovered as a needed growth factor for the bacterium Leuconostoc citrovorum in 1948, by Sauberlich and Baumann. This resulted in it being called \"citrovorum factor\", meaning citrovorum growth factor. It had an unknown structure, but was found to be a folate derivative that had to be metabolized in the liver before it could support the growth of L. citrovorum. The synthesis of citrovorum factor by liver cells in culture was eventually accomplished from pteroylglutamic acid in the presence of suitable concentrations of ascorbic acid. The simultaneous addition of sodium formate to such systems increased citrovorum factor activity in the cell-free supernatants (producing, as is now known, the 5-formyl derivative). From this method of preparation of large amounts of the factor, its structure as levo-folinic acid (5-formyl tetrahydrofolic acid) was eventually deduced.\n\nIn September 2025, the US Food and Drug Administration (FDA) initiated the process of approving leucovorin calcium tablets for the treatment of cerebral folate deficiency, a condition associated with developmental delays, autistic features, seizures, and movement issues. \n\nOn 10 March 2026, the FDA approved leucovorin tablets for FOLR1-related cerebral folate transport deficiency in children and adults.","wiki_society_and_culture":"== Society and culture ==\n=== Names ===\n\nFolinic acid should be distinguished from folic acid (vitamin B<sub>9</sub>). However, folinic acid is a vitamer of folic acid and has the full vitamin activity of this vitamin. Levofolinic acid and its salts are the 2S-form of the molecule. They are the only forms of the molecule that are known to be biologically active.\n\nIt is generally administered as the calcium or sodium salt (calcium folinate [<nowiki/>INN], sodium folinate, leucovorin calcium, leucovorin sodium)."},"commercial":{"launchDate":"2008","_launchSource":"DrugCentral (FDA 2008-03-07, SPECTRUM PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4384","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Levofolinic%20acid","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levofolinic acid","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Folinic_acid","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T12:19:38.272650","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:15.947943+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"mesna","drugSlug":"mesna","fdaApproval":"1988-12-30","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dexrazoxane","drugSlug":"dexrazoxane","fdaApproval":"1995-05-26","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"leucovorin","drugSlug":"leucovorin","fdaApproval":"1952-06-20","patentExpiry":"Dec 23, 2044","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"amifostine","drugSlug":"amifostine","fdaApproval":"1995-12-08","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"rasburicase","drugSlug":"rasburicase","fdaApproval":"2002-07-12","relationship":"same-class"},{"drugName":"palifermin","drugSlug":"palifermin","fdaApproval":"2004-12-15","relationship":"same-class"},{"drugName":"glucarpidase","drugSlug":"glucarpidase","fdaApproval":"2012-01-17","relationship":"same-class"},{"drugName":"arginine","drugSlug":"arginine","fdaApproval":"1973-02-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lysine","drugSlug":"lysine","fdaApproval":"","relationship":"same-class"},{"drugName":"trilaciclib","drugSlug":"trilaciclib","fdaApproval":"2021-02-12","patentExpiry":"Oct 25, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"levofolinic acid","indications":{"approved":[{"name":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults with metastatic colorectal cancer","usPrevalence":153000,"globalPrevalence":1900000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Bone Marrow Suppression due to Folic Acid Antagonism","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adult and pediatric patients"},{"name":"Folic acid deficiency","source":"DrugCentral","snomedId":190633005,"regulator":"FDA","eligibility":"Not indicated for patients with pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12"},{"name":"Malignant tumor of stomach","source":"DrugCentral","snomedId":363349007,"regulator":"FDA","eligibility":"Not specified"},{"name":"Megaloblastic anemia","source":"DrugCentral","snomedId":53165003,"regulator":"FDA","eligibility":"Not indicated for patients with pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12"},{"name":"Methotrexate Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adult and pediatric patients","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2015[INST])"},{"name":"Pyrimethamine Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adult and pediatric patients"},{"name":"Small intestine cancer","source":"DrugCentral","snomedId":363509000,"regulator":"FDA","eligibility":"Not specified"},{"name":"Sulfadiazine Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adult and pediatric patients"},{"name":"Trimethoprim Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adult and pediatric patients"},{"name":"Trimetrexate Toxicity","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"mesna","brandName":"mesna","genericName":"mesna","approvalYear":"1988","relationship":"same-class"},{"drugId":"dexrazoxane","brandName":"dexrazoxane","genericName":"dexrazoxane","approvalYear":"1995","relationship":"same-class"},{"drugId":"leucovorin","brandName":"leucovorin","genericName":"leucovorin","approvalYear":"1952","relationship":"same-class"},{"drugId":"amifostine","brandName":"amifostine","genericName":"amifostine","approvalYear":"1995","relationship":"same-class"},{"drugId":"rasburicase","brandName":"rasburicase","genericName":"rasburicase","approvalYear":"2002","relationship":"same-class"},{"drugId":"palifermin","brandName":"palifermin","genericName":"palifermin","approvalYear":"2004","relationship":"same-class"},{"drugId":"glucarpidase","brandName":"glucarpidase","genericName":"glucarpidase","approvalYear":"2012","relationship":"same-class"},{"drugId":"arginine","brandName":"arginine","genericName":"arginine","approvalYear":"1973","relationship":"same-class"},{"drugId":"lysine","brandName":"lysine","genericName":"lysine","approvalYear":"","relationship":"same-class"},{"drugId":"trilaciclib","brandName":"trilaciclib","genericName":"trilaciclib","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":["Pancreatic Carcinoma"],"enrollment":130,"completionDate":"2025-12"},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":["Advanced Malignant Solid Neoplasm","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Malignant Solid Neoplasm","Malignant Female Reproductive System Neoplasm","Metastatic HER2-Negative Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Solid Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Unresectable HER2-Negative Breast Carcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":2900,"completionDate":"2030-07-01"},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":["Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma"],"enrollment":94,"completionDate":"2030-12"},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":["Metastatic Colorectal Adenocarcinoma","Stage IV Colorectal Cancer AJCC v7"],"enrollment":120,"completionDate":"2027-06-01"},{"nctId":"NCT05564403","phase":"PHASE2","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-09","conditions":["Advanced Biliary Tract Carcinoma","Advanced Gallbladder Carcinoma","Advanced Intrahepatic Cholangiocarcinoma","Recurrent Biliary Tract Carcinoma","Recurrent Gallbladder Carcinoma","Recurrent Intrahepatic Cholangiocarcinoma","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage III Hilar Cholangiocarcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Hilar Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Biliary Tract Carcinoma","Unresectable Gallbladder Carcinoma","Unresectable Intrahepatic Cholangiocarcinoma"],"enrollment":66,"completionDate":"2026-05-01"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":["Metastatic Colorectal Adenocarcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Adenocarcinoma"],"enrollment":24,"completionDate":"2026-12-31"},{"nctId":"NCT06628310","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-12-13","conditions":["Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma"],"enrollment":180,"completionDate":"2030-10"},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":["Colon Adenocarcinoma","Stage IIA Colon Cancer AJCC v7","Stage IIB Colon Cancer AJCC v7","Stage IIC Colon Cancer AJCC v7"],"enrollment":2431,"completionDate":"2026-04-11"},{"nctId":"NCT07283939","phase":"NA","title":"Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2026-02-13","conditions":["Ampulla of Vater Carcinoma","Appendix Carcinoma","Carcinoma of Unknown Primary With Gastrointestinal Profile","Colon Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Gastroesophageal Junction Carcinoma","Malignant Digestive System Neoplasm","Rectal Carcinoma","Small Intestinal Carcinoma"],"enrollment":420,"completionDate":"2030-05-02"},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":["Lymphoma"],"enrollment":65,"completionDate":"2028-12-10"},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":["Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"enrollment":614,"completionDate":"2029-08-31"},{"nctId":"NCT07490301","phase":"PHASE2,PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma","PDAC"],"enrollment":900,"completionDate":"2031-06"},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":["Metastatic Colorectal Cancer"],"enrollment":390,"completionDate":"2028-04"},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":["Metastatic Colorectal Carcinoma","Metastatic Malignant Neoplasm in the Liver","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma"],"enrollment":408,"completionDate":"2034-06-30"},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":["Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Oligometastatic Esophageal Adenocarcinoma","Oligometastatic Gastric Adenocarcinoma","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Gastric Cancer AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8"],"enrollment":314,"completionDate":"2028-03-31"},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":["Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":176,"completionDate":"2026-12-31"},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":["Colon Adenocarcinoma","Rectal Adenocarcinoma"],"enrollment":477,"completionDate":"2030-10-27"},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":["Colorectal Neoplasms"],"enrollment":1000,"completionDate":"2032-01-30"},{"nctId":"NCT05179889","phase":"PHASE2,PHASE3","title":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","status":"RECRUITING","sponsor":"Chungnam National University Hospital","startDate":"2021-07-06","conditions":["Colon Cancer Stage III"],"enrollment":308,"completionDate":"2031-03-15"},{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":["Esophageal Cancer, Squamous Cell"],"enrollment":15,"completionDate":"2022-07-05"},{"nctId":"NCT02359968","phase":"PHASE2","title":"PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02-26","conditions":["Esophageal Neoplasms","Gastro-esophageal Junction Cancer"],"enrollment":106,"completionDate":"2024-02-09"},{"nctId":"NCT07011576","phase":"PHASE2","title":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-09-29","conditions":["Colon Cancer","Rectal Cancer","Colorectal Cancer","Colorectal Cancer (CRC)"],"enrollment":60,"completionDate":"2027-06"},{"nctId":"NCT05702229","phase":"PHASE2","title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-01-16","conditions":["Gastric Cancer"],"enrollment":163,"completionDate":"2029-05-31"},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":["Colorectal Cancer"],"enrollment":200,"completionDate":"2027-02-26"},{"nctId":"NCT06469944","phase":"PHASE1,PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":["Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Neoplasms","Esophageal Cancer"],"enrollment":160,"completionDate":"2029-09-12"},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":["Colorectal Neoplasms"],"enrollment":400,"completionDate":"2029-07-27"},{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":["Unresectable Pancreatic Cancer"],"enrollment":90,"completionDate":"2027-05-31"},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":25,"completionDate":"2028-01-31"},{"nctId":"NCT00905047","phase":"PHASE3","title":"Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-11-14","conditions":["Colorectal Cancer"],"enrollment":89,"completionDate":"2011-09"},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":222,"completionDate":"2030-12-01"},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":30,"completionDate":"2029-03-11"},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":["Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer","Colorectal Cancer","Advanced Solid Tumor","Metastatic Solid Tumor"],"enrollment":750,"completionDate":"2030-01"},{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":["Advanced Esophageal Squamous Cell Carcinoma","Unresectable Esophageal Squamous Cell Carcinoma"],"enrollment":50,"completionDate":"2029-06-30"},{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":["Pancreatic Cancer Resectable"],"enrollment":30,"completionDate":"2029-01-31"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":["Leukemia"],"enrollment":171,"completionDate":"2026-03-03"},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":500,"completionDate":"2028-09-30"},{"nctId":"NCT06780111","phase":"PHASE1,PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":298,"completionDate":"2032-01-04"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":["Metastatic Adenocarcinoma of the Pancreas"],"enrollment":770,"completionDate":"2025-02-18"},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":1007,"completionDate":"2025-04-23"},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":["Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Stage I Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer"],"enrollment":46,"completionDate":"2024-01-14"},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":120,"completionDate":"2025-04-23"},{"nctId":"NCT05346484","phase":"PHASE1","title":"A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2022-05-17","conditions":["Solid Tumor","Solid Carcinoma","Solid Tumor, Adult","Metastatic Cancer","Advanced Solid Tumor","Cholangiocarcinoma","Bile Duct Cancer"],"enrollment":66,"completionDate":"2026-01-12"},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":["Pancreatic Cancer"],"enrollment":84,"completionDate":"2028-12-31"},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":["Colorectal Cancer"],"enrollment":528,"completionDate":"2029-06-01"},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":["Metastatic Pancreatic Adenocarcinoma","Recurrent Pancreatic Carcinoma","Stage IV Pancreatic Cancer AJCC v6 and v7"],"enrollment":123,"completionDate":"2026-03-17"},{"nctId":"NCT05677490","phase":"PHASE3","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-01-31","conditions":["Advanced Esophageal Adenocarcinoma","Advanced Gastric Adenocarcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Unresectable Esophageal Adenocarcinoma","Unresectable Gastric Adenocarcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma"],"enrollment":382,"completionDate":"2028-11-08"},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":["Metastatic Pancreatic Cancer"],"enrollment":162,"completionDate":"2027-10-30"},{"nctId":"NCT05846867","phase":"PHASE1,PHASE2","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-05-08","conditions":["Colorectal Cancer"],"enrollment":170,"completionDate":"2026-08-11"},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":["Rectal Cancer"],"enrollment":582,"completionDate":"2029-06-01"},{"nctId":"NCT04094688","phase":"PHASE3","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-29","conditions":["Colorectal Adenocarcinoma"],"enrollment":455,"completionDate":"2026-07-01"},{"nctId":"NCT07446465","phase":"PHASE4","title":"FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ye Xu","startDate":"2026-03-01","conditions":["Colorectal Cancer (Locally Advanced or Metastatic)","Colorectal Cancer Microsatellite Stable (MSS)"],"enrollment":42,"completionDate":"2027-01-31"},{"nctId":"NCT06047379","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":["Diffuse Astrocytoma, IDH-Mutant","Glioblastoma, IDH-wildtype","Brain Metastases, Adult","Cervical Cancer","Colorectal Cancer","Esophageal Cancer","Esophageal Squamous Cell Carcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Microsatellite Instability-High Solid Malignant Tumor","Mismatch Repair Deficient Solid Malignant Tumor","Microsatellite Instability-High Colorectal Cancer","Mismatch Repair Deficient Colorectal Cancer","Non-small Cell Lung Cancer","Renal Cell Carcinoma","Small Cell Lung Cancer","Squamous Cell Carcinoma","Urothelial Carcinoma"],"enrollment":134,"completionDate":"2027-08-31"},{"nctId":"NCT04068610","phase":"PHASE1,PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":["Metastatic Microsatellite-stable Colorectal Cancer"],"enrollment":61,"completionDate":"2026-11-24"},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":["Liver Metastases From Colorectal Cancer (mCRC)"],"enrollment":16,"completionDate":"2027-02-28"},{"nctId":"NCT07412613","phase":"PHASE3","title":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2026-03-15","conditions":["Resectable Colon Cancer","MSI-H/dMMR Colorectal Cancer"],"enrollment":386,"completionDate":"2031-03-15"},{"nctId":"NCT07437287","phase":"PHASE2,PHASE3","title":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-07","conditions":["Biliary Tract Cancer (BTC)"],"enrollment":160,"completionDate":"2031-10"},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":["Clinical Stage I Esophageal Adenocarcinoma AJCC v8","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8"],"enrollment":99,"completionDate":"2031-05-30"},{"nctId":"NCT07176182","phase":"PHASE2","title":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-03-01","conditions":["Rectal Cancer Patients","Rectal Cancer Stage II","Rectal Cancer Stage III"],"enrollment":236,"completionDate":"2031-03-01"},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":330,"completionDate":"2028-09-09"},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":["Advanced Malignant Neoplasm","Colorectal Carcinoma Metastatic in the Liver","Metastatic Malignant Neoplasm in the Liver","Refractory Malignant Neoplasm"],"enrollment":38,"completionDate":"2026-12-31"},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":["Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Myelodysplastic Syndrome","Recurrent Juvenile Myelomonocytic Leukemia","Refractory Childhood Acute Myeloid Leukemia","Refractory Childhood Myelodysplastic Syndrome","Refractory Juvenile Myelomonocytic Leukemia"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent B Lymphoblastic Lymphoma","Refractory B Acute Lymphoblastic Leukemia","Refractory B Lymphoblastic Lymphoma"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT05983367","phase":"PHASE2","title":"A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Inspirna, Inc.","startDate":"2023-10-10","conditions":["Colorectal Cancer","Metastatic Colon Cancer"],"enrollment":76,"completionDate":"2025-03-31"},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":["Pancreatic Cancer Metastatic","Pancreatic Ductal Adenocarcinoma","Advanced Pancreatic Cancer"],"enrollment":150,"completionDate":"2025-03-05"},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":["Small Bowel Adenocarcinoma"],"enrollment":36,"completionDate":"2028-08"},{"nctId":"NCT07415031","phase":"PHASE2","title":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","status":"NOT_YET_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2026-05-16","conditions":["Solid Tumors"],"enrollment":170,"completionDate":"2028-02-16"},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":["Drug/Agent Toxicity by Tissue/Organ","Leukemia"],"enrollment":800,"completionDate":"2019-06"},{"nctId":"NCT05466799","phase":"PHASE2","title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoSil Medical Limited","startDate":"2023-04-26","conditions":["Locally Advanced Pancreatic Cancer"],"enrollment":88,"completionDate":"2027-07"},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":["Colorectal Neoplasms"],"enrollment":700,"completionDate":"2029-04-13"},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction (GEJ) Adenocarcinoma","Pancreatic Adenocarcinoma"],"enrollment":398,"completionDate":"2027-05-31"},{"nctId":"NCT03504397","phase":"PHASE3","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-21","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":565,"completionDate":"2026-09-30"},{"nctId":"NCT06219941","phase":"PHASE2","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer","Biliary Tract Cancer","Pancreatic Ductal Adenocarcinoma"],"enrollment":224,"completionDate":"2027-09-30"},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":["Rectal Cancer"],"enrollment":364,"completionDate":"2031-12-28"},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":["Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers"],"enrollment":350,"completionDate":"2029-02-25"},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":["Metastatic Colorectal Cancer"],"enrollment":0,"completionDate":"2025-09-19"},{"nctId":"NCT03426904","phase":"PHASE3","title":"Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":["Colon Cancer"],"enrollment":708,"completionDate":"2031-12-28"},{"nctId":"NCT04340141","phase":"PHASE3","title":"Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2020-10-13","conditions":["Pancreatic Adenosquamous Carcinoma","Resectable Pancreatic Adenocarcinoma","Pancreatic Cancer"],"enrollment":358,"completionDate":"2030-11-01"},{"nctId":"NCT07214298","phase":"PHASE1,PHASE2","title":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-01","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":35,"completionDate":"2028-10-01"},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":["Locally Advanced Rectal Cancer"],"enrollment":25,"completionDate":"2028-10-31"},{"nctId":"NCT07391566","phase":"PHASE1,PHASE2","title":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","status":"NOT_YET_RECRUITING","sponsor":"Luye Pharma Group Ltd.","startDate":"2026-03-31","conditions":["Metastatic Colorectal Cancer (mCRC)"],"enrollment":99,"completionDate":"2028-12-31"},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":["Advanced Colorectal Cancer"],"enrollment":583,"completionDate":"2029-12"},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":["Liver Metastases"],"enrollment":120,"completionDate":"2027-02-28"},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":["Colorectal Cancer","Cholangiocarcinoma"],"enrollment":35,"completionDate":"2024-06-27"},{"nctId":"NCT05546853","phase":"PHASE1","title":"Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2023-03-28","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":43,"completionDate":"2025-06-16"},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":["Metastatic Colorectal Cancer (mCRC)"],"enrollment":480,"completionDate":"2030-10"},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":["Metastatic Colorectal Cancer"],"enrollment":34,"completionDate":"2029-10"},{"nctId":"NCT00556413","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2005-09","conditions":["Colorectal Cancer"],"enrollment":42,"completionDate":"2011-11-17"},{"nctId":"NCT07176312","phase":"PHASE2","title":"Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2026-01-16","conditions":["Gastroesophageal Adenocarcinoma","First Line Therapy","HER2 + Gastric Cancer","PDL-1","Metastases"],"enrollment":80,"completionDate":"2029-03"},{"nctId":"NCT07061080","phase":"PHASE2","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-12-18","conditions":["Advanced Neuroendocrine Carcinomas of The Digestive System","Advanced Neuroendocrine Carcinomas Unknown Primary Origin"],"enrollment":87,"completionDate":"2028-12"},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":["Stage II Colon Cancer","Stage III Colon Cancer","HER2-positive Colon Cancer","RAS Wild-type Colon Cancer"],"enrollment":477,"completionDate":"2029-12"},{"nctId":"NCT07381400","phase":"PHASE2","title":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-01","conditions":["Rectal Cancer"],"enrollment":128,"completionDate":"2031-12-31"},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":["Rectal Cancer"],"enrollment":550,"completionDate":"2030-08"},{"nctId":"NCT02912559","phase":"PHASE3","title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-16","conditions":["Colon Adenocarcinoma","DNA Repair Disorder","Lynch Syndrome","Stage III Colon Cancer AJCC v8"],"enrollment":712,"completionDate":"2026-12-18"},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":["Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":356,"completionDate":"2030-10-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous, Oral","formulation":"Capsule, Injection","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Biopar delta-FORTE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Levoleucovorin"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"levoleucovorin"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Levoleucovorin"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Fusilev"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"LEVOLEUCOVORIN"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"LEVOLEUCOVORIN CALCIUM"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Levoleucovorin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Levoleucovorin Calcium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Fusilev"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000182085","MMSL":"132962","NDDF":"005532","UNII":"WA16A5Y52X","VUID":"4028507","CHEBI":"CHEBI:63606","VANDF":"4028507","INN_ID":"6883","RXNORM":"1648126","UMLSCUI":"C2721771","chemblId":"CHEMBL1908841","ChEMBL_ID":"CHEMBL1908841","DRUGBANK_ID":"DB11596","PDB_CHEM_ID":"FOZ","PUBCHEM_CID":"135398559","SNOMEDCT_US":"395769006","SECONDARY_CAS_RN":"419573-16-3","MESH_DESCRIPTOR_UI":"D058766"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2008-","companyName":"Spectrum Pharms","relationship":"Original Developer"},{"period":"2018","companyName":"Pfizer Japan Inc.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.1 hours","clearance":"4.1 mL/min/kg","volumeOfDistribution":"0.27 L/kg"},"publicationCount":45,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"V03AF04","allCodes":["V03AF04","V03AF10"]},"biosimilarFilings":[],"originalDeveloper":"Spectrum Pharms","recentPublications":[{"date":"2025 Apr","pmid":"40089969","title":"A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study.","journal":"Drugs & aging"},{"date":"2023 Feb 15","pmid":"36793106","title":"Strategic use of levofolinic acid for methotrexate-induced side effects in juvenile idiopathic arthritis: a prospective observational study.","journal":"Pediatric rheumatology online journal"},{"date":"2020 Jan","pmid":"32381870","title":"[A Case of a Migrating Central Venous Catheter in the Internal Jugular Vein Diagnosed Using Ultrasonography in a Patient with Right-Sided NeckPain during Chemotherapy].","journal":"Gan to kagaku ryoho. Cancer & chemotherapy"},{"date":"2019 Oct","pmid":"31394027","title":"Toxoplasma gondii-induced brachial plexus neuropathy after allogeneic hematopoietic stem cell transplantation.","journal":"Transplant infectious disease : an official journal of the Transplantation Society"},{"date":"2018","pmid":"28685492","title":"Role of Intramuscular Levofolinate Administration in the Treatment of Hereditary Folate Malabsorption: Report of Three Cases.","journal":"JIMD reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Spectrum Pharms","companyId":"spectrum-pharms","modality":"Small molecule","firstApprovalDate":"2008","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-03-07T00:00:00.000Z","mah":"SPECTRUM PHARMS","brand_name_local":null,"application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2018-09-21T00:00:00.000Z","mah":"Pfizer Japan Inc.","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"11541012","territory":"US","patent_type":null,"expiry_date":"2039-03-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:15.947943+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}